AI Joins Top Heart Hospital to Unmask Silent Killer Disease

NEW YORK, NY – April 30, 2026 – The fight against one of cardiology's most insidious diseases has gained a powerful new ally. The Mount Sinai Health System, one of the nation's most prestigious healthcare institutions, has begun deploying an advanced artificial intelligence tool designed to unmask severe aortic stenosis, a common but dangerously under-diagnosed heart valve condition.

The deployment of EchoSolv AS, developed by Australian medical technology firm Echo IQ, at a facility ranked No. 1 in New York for cardiology represents a major milestone. It signals a growing confidence in AI's ability to augment clinical expertise and fundamentally improve how life-threatening diseases are identified.

A New Watchdog in a Premier Heart Hospital

Mount Sinai's decision to integrate EchoSolv AS into its workflow is a significant endorsement. The Mount Sinai Fuster Heart Hospital is ranked No. 2 in the entire nation for Cardiology, Heart & Vascular Surgery by U.S. News & World Report. With seven hospitals and over 400 outpatient practices, the system's vast echocardiography footprint provides a real-world crucible to test and prove the value of AI-driven diagnostics at scale.

EchoSolv AS functions as an AI-powered decision support tool. It analyzes echocardiogram data to provide a “measurement-based second look,” helping cardiologists more consistently identify patients with severe aortic stenosis who might otherwise be missed. The goal is not to replace physicians, but to empower them with a highly trained digital assistant.

“We are proud to work with Mount Sinai Health System, an institution recognised for excellence in cardiovascular care, clinical innovation, and leadership in medicine,” said Nick Lubbers, US President and General Manager for Echo IQ, in a statement. “This deployment is an important step in our US commercial growth and underscores increasing interest in solutions that can support cardiologists within routine echocardiography workflows.”

The enthusiasm is shared by clinicians on the front lines. Dr. Stamatios Lerakis, Director of the Cardiovascular Imaging Program for Mount Sinai Health System, highlighted the technology's potential to address a critical diagnostic gap. “This product can highlight patients with aortic stenosis that can be otherwise under-diagnosed, remain untreated and as a result, not benefit from the tremendous therapeutic advancements in the space of aortic valve diseases,” Dr. Lerakis stated. He emphasized its role as a supportive tool, adding, “I see this as an adjunct for the echocardiographer who will always have the final say on the interpretation! This product will only strengthen patient care.”

Tackling a Silent Killer

The problem EchoSolv AS aims to solve is both widespread and deadly. Aortic stenosis (AS) involves the narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body. It is the most common form of valvular heart disease, affecting an estimated 5% of people by age 65 and over 12% of those over 75.

Its danger lies in its subtlety. Symptoms like fatigue, shortness of breath, or chest pain are often dismissed by patients as normal signs of aging. This allows the disease to progress silently while the heart muscle works harder, leading to irreversible damage. Research shows that once severe symptoms develop, the prognosis is grim, with mortality rates as high as 50% within two years without valve replacement.

Compounding the issue are significant diagnostic challenges. Studies suggest that the detection of severe AS may be missed in up to half of all cases. Echocardiography, the standard diagnostic tool, is highly dependent on operator skill, and complex cases, such as those with low blood flow, can lead to underestimation of the disease's severity. This diagnostic blind spot means thousands of patients who could benefit from life-saving valve replacement therapies are never identified.

The Promise of a 'Second Look'

This is the gap Echo IQ's technology, which received FDA 510(k) clearance in October 2024, is designed to fill. The AI behind EchoSolv AS was trained on one of the world's largest echo databases, learning to recognize the complex patterns of severe aortic stenosis by analyzing millions of data points.

When integrated into a hospital's workflow, the software automatically analyzes measurements from a patient's echocardiogram. Within minutes, it can flag patients who meet the clinical guidelines for severe disease, providing a crucial safety net. Validation studies have demonstrated its high degree of accuracy, with one study at Harvard's Beth Israel Deaconess Medical Center showing a sensitivity of 82.2% and a specificity of 98.1% for identifying the condition. The company reports an overall detection rate of up to 97%.

This ability to consistently and accurately screen for the disease at scale could transform patient triage, ensuring high-risk individuals are prioritized for further review and potential intervention before their condition becomes untreatable.

A Strategic Move in a Competitive Field

For Echo IQ, the Mount Sinai deployment is a landmark achievement in its strategy to penetrate the lucrative and highly competitive U.S. healthcare market. As a relatively small Australian firm, securing a partnership with a top-tier American institution provides invaluable validation and a powerful case study for other hospital systems.

The field of AI in cardiology is rapidly heating up. A host of innovative companies are developing AI-powered tools to automate echo analysis, detect various forms of heart disease, and streamline clinical workflows. Echo IQ's focused approach on severe aortic stenosis and its successful integration into a leading hospital's workflow gives it a key strategic advantage.

The company is also pursuing a broader strategy. It is actively working to secure reimbursement codes to create financial incentives for adoption and has a similar agreement with the Mayo Clinic to support the future rollout of another product, EchoSolv HF, for heart failure, pending its own FDA clearance. This multi-pronged approach, backed by recent capital raises, positions Echo IQ for sustained growth as it navigates its early, pre-profitability stage.

The Bigger Picture: AI's System-Wide Integration

The adoption of EchoSolv AS is not an isolated experiment for Mount Sinai. It is a single, potent example of the health system's deep and system-wide commitment to integrating artificial intelligence into every facet of patient care. Mount Sinai was the first academic medical center to establish a Department of Artificial Intelligence and Human Health and currently has more than 20 different AI-based tools in production.

These tools range from algorithms that predict a patient's risk of malnutrition or falls to systems that help nurses identify patients prone to bedsores. This broader strategy, described as "human-led, human-centered" AI, aims to use technology to augment the skills of care teams, improve efficiency, and ultimately deliver better outcomes. By adding EchoSolv AS to its arsenal, Mount Sinai is applying this philosophy to one of the most critical areas of medicine, demonstrating how targeted AI can help solve stubborn clinical challenges and save lives.